×

Sign up to receive
the latest NanoTemper news, product updates, event announcements and more

First Name
Last Name
Company Name
Country
State
Province
State
Region
State
Canton
Agree to Subscribe & Privacy Policy*
*I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
Thank you!
Error - something went wrong!
   

Thermal Stability Buffer Screening of Therapeutic Antibodies

The development of therapeutic antibodies requires optimal formulations for long-term antibody stability. For this, buffer screening approaches are routinely used, in which the thermal stability of a given antibody in different buffers are tested. The buffers typically vary regarding buffer substances, pH values, salt concentrations and other excipients. 

The prerequisite for such screening approaches are high measurement precision, low sample consumption, and high throughput. Moreover, it is highly desirable to measure under native conditions, without dilution of the antibody or the requirement to use reporter dyes or other modifications. 

Here we present nanoDSF, a label-free, native DSF technique, as the method of choice to perform rapid and precise buffer screening projects for therapeutic antibodies during the drug development process.

Previous
Analysis of formulation-dependent colloidal and conformational stability of monoclonal antibodies
Analysis of formulation-dependent colloidal and conformational stability of monoclonal antibodies

Up next
Detergent Screen for solubilized membrane proteins – Case study on the SLAC-protein HiTehA from Haemophilus influenzae
Detergent Screen for solubilized membrane proteins – Case study on the SLAC-protein HiTehA from Haemophilus influenzae

Have a question?

Contact Specialist